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Abstract
Introduction—Black women have an increased risk of adverse pregnancy outcomes and the 
characteristics of thrombotic risk factors in this population are unknown. The objective of this 
study was to examine the racial differences in thrombotic risk factors among women with adverse 
pregnancy outcomes.
Methods—Uniform data were collected in women with adverse pregnancy outcomes (pregnancy 
losses, intrauterine growth restriction (IUGR), prematurity, placental abruption and preeclampsia) 
referred to Thrombosis Network Centers funded by the Centers for Disease Control and 
Prevention (CDC).
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Results—Among 343 white and 66 black women seen for adverse pregnancy outcomes, protein 
S and antithrombin deficiencies were more common in black women. The prevalence of 
diagnosed thrombophilia was higher among whites compared to blacks largely due to Factor V 
Leiden mutation. The prevalence of a personal history of venous thromboembolism (VTE) did not 
differ significantly by race. A family history of VTE, thrombophilia, and stroke or myocardial 
infarction (MI) was higher among whites. Black women had a higher body mass index, and a 
higher prevalence of hypertension, while the prevalence of sickle cell disease was approximately 
27 fold higher compared to the general US black population.
Conclusions—Thrombotic risk factors differ significantly in white and black women with 
adverse pregnancy outcomes. Such differences highlight the importance of considering race 
separately when assessing thrombotic risk factors for adverse pregnancy outcomes.
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Introduction
There are significant disparities in rates of adverse pregnancy outcomes between black and 
white women [1]. In the US, 69% of pregnancies among white women end in live birth 
compared to 49% of pregnancies in black women [1], and black women have increased rates 
of fetal loss compared to white women (11.13 vs 4.79 per 1000 live births) [2]. A 
multicenter US study limited to women with early access to prenatal care reported an 
approximately 3–4 fold increased risk of both early and late fetal demise in black women 
compared to white women after adjusting for multiple maternal and socioeconomic 
characteristics [3]. In addition, significantly higher rates of intrauterine growth restriction, 
preeclampsia, preterm birth, and placental abruption have been found in black women 
compared to white women [2,3]. Despite improvements in obstetric care, major racial 
disparities in adverse pregnancy outcomes persist and remain unexplained.
Thrombotic risk factors have been associated with pregnancy complications [4–8]. Many 
previous studies have found an association between inherited thrombophilia and adverse 
pregnancy outcomes, however there has been wide variability in the strength of the 
association and some studies have not found a relationship [4,6–12]. Despite significant 
racial disparities in rates of adverse pregnancy outcomes, most studies examining the 
relationship of thrombotic risk factors in women with adverse pregnancy outcomes have 
been performed in white populations, and have focused on Factor V Leiden and prothrombin 
gene mutations [9–12], thrombotic risk factors known to be less prevalent among black 
populations [13,14]. There is very limited information on thrombophilia and other 
thrombotic risk factors in black women with adverse pregnancy outcomes. The objective of 
this study was to compare the characteristics of thrombotic risk factors among black and 
white women with adverse pregnancy outcomes receiving care and participating in a multi-
site registry at US Thrombosis Network Centers.
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Consecutive patients seen in consultation at any of the Thrombosis and Hemostasis 
Research and Prevention Network Centers, funded by the Centers for Disease Control and 
Prevention (CDC), were approached for participation in a patient registry regardless of the 
reason for their visit, age, sex, or race. After obtaining informed consent, a standardized data 
collection form was completed by center staff during initial and subsequent visits. Uniform 
data were prospectively collected from August 2003 to March 2011 and were entered into a 
web-based registry housed at the CDC, Division of Blood Disorders. De-identified data 
were submitted by unique patient study identification number. Institutional Review Board 
approval was obtained at each of the network centers and the CDC and continuing approval 
obtained annually. Information for the patient registry was collected by network center 
medical providers at the time of the visit and included demographic and clinical 
characteristics, concurrent medical conditions, family history, laboratory and radiologic 
tests, diagnosis, and treatments prescribed. The CDC funded Thrombosis Network Centers 
and registry have been previously described [15–17].
To examine the prevalence of thrombotic risk factors in women with adverse pregnancy 
outcomes, we searched the patient registry for women age 15 years and older at enrollment 
who had been referred to one of the Thrombosis and Hemostasis Network Centers for 
prepregnancy, pregnancy, or postpartum consultation. From this group of women, we 
included only women seen for adverse pregnancy outcomes. We further restricted analysis 
to women of black or white race and compared thrombotic and clinical characteristics 
between the two racial groups.
Adverse pregnancy outcomes were defined as a documented history of pregnancy loss or 
losses, intrauterine growth restriction (IUGR), preterm delivery, placental abruption and/or 
preeclampsia. Race was self-identified. Those who selected more than one race were 
categorized as “other” race and included in the “other” race subgroup. In addition to 
individuals selecting more than one race, the “other” race category also included Asians, 
American Indian, Alaskan native, and Pacific Islanders. The “other” racial category was not 
included in the data analyzed.
The registry included a history of medical comorbidites including diabetes, hypertension, 
sickle cell disease, cancer, myocardial infarction and stroke for each woman. The history 
and clinical presentation of diagnosed thromboembolic events, locations of thrombi, and 
associated risks such as surgery, trauma, contraceptive use, and hormonal replacement 
therapy were also collected. Self-reported family histories of thromboembolism, adverse 
pregnancy outcomes, and diagnosed thrombophilia were also obtained. Medical 
comorbidities, thromboembolic events, associated thrombotic risk, and family history were 
compared between the two racial groups.
For this study, thrombophilia was defined as factor V Leiden or prothrombin G20210A 
mutations, deficiency of antithrombin, protein C, or protein S, or antiphospholipid antibody 
syndrome (APS) at enrollment or by evaluation by the Center. For most diagnoses made 
prior to evaluation at the center, the thrombophilia diagnosis was confirmed by testing 
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performed on-site at the network centers. The diagnosis of APS was based on the Sapporo 
classification [18].
A history of venous thromboembolism (VTE) was defined as VTE diagnosed by 
venography, angiography, duplex ultrasonography, impedence plethysmography, computed 
tomographic venography or angiography, MRI, or high probability ventilation perfusion 
scan.
The prevalence of a.priori selected demographic and clinical characteristics were calculated 
and compared between blacks and whites. For categorical variables Pearson’s chi-square test 
was used and in the case of small cell sizes (<5) Fisher’s exact p values were reported. The 
prevalence of protein S deficiency was also evaluated in the subgroup of women who were 
not known to be pregnant at the time of study enrollment. Mean values were computed for 
the continuous variables of age and body mass index (BMI) at the time of enrollment and 
differences between the racial groups were assessed using Student’s t-test. A p-value < 0.05 
was considered statistically significant for the analyses. The data were analyzed using SAS 
statistical package version 9.2(SAS Institute, Cary, NC).
Results
Between August 2003 and March 2011, 833 women, (631 white, 152 black, and 50 of other 
or missing race) were referred to a participating Network Center for pregnancy, pre-
pregnancy, or postpartum consultation or management and enrolled into the patient registry. 
The mean age at enrollment was 34.8 ± 10.5 years. Of these 833 women, 434 were seen for 
a history of adverse pregnancy outcome (343 white, 66 black, and 25 of other or missing 
races). The adverse pregnancy outcomes included pregnancy loss or recurrent losses, IUGR, 
preterm delivery, preeclampsia, and placental abruption.
Among the 409 women of black or white race with an adverse pregnancy outcome, the mean 
age at enrollment was 39.1 ± 11.8 years and 33.8 ± 10.4 years for white and black women 
respectively (p < 0.01). The average body mass index (BMI) at enrollment was higher (31.9 
± 9.6 vs 29.1 ± 11.1 kg/m2, p = 0.07) in black women and the prevalence of non-pregnant 
BMI ≥ 25 was significantly higher in black women than white women (86.2% vs 63.4%, p = 
0.01) (Table 1). The adverse pregnancy outcomes did not differ significantly by race except 
for second trimester loss, which was more common among black women (33.3% vs 21.9%, 
p = 0.05) (Table 2).
The prevalence of diagnosed thrombophilia differed by race. Overall, thrombophilia was 
more common in white women with adverse pregnancy outcomes compared to black women 
(44% vs 30.3%, p = 0.04) (Table 3), although this difference was primarily due to the 
difference in factor V Leiden mutation (19% vs 3%, p < 0.01). However, protein S 
deficiency was significantly more common in black women (15.2 % vs 5.8 %, p = 0.02) 
(Table 3). When assessed among the subgroup of women who were not pregnant at study 
enrollment (252 white and 32 black), protein S deficiency was still more common in black 
women but the difference did not reach statistical significance (13.5 % vs 5.5 %, p = 0.08). 
None of the women with protein S deficiency had sickle cell disease, renal disease, or HIV. 
Philipp et al. Page 4













Antithrombin deficiency was also more common among black women (6% vs 1.5%, p = 
0.04). There were no racial differences in the frequency of laboratory testing for protein S or 
antithrombin.
A personal history of VTE, including pulmonary embolism and/or deep vein thrombosis, did 
not differ significantly by race except for surgery associated VTE which was significantly 
more common in white women (10.8% vs 1.5%, p = 0.02) (Table 4). Hypertension (25.8% 
vs 11.4%, p < 0.01) and sickle cell disease (4.6% vs 0 p < 0.01) were more common among 
black women than white women with adverse pregnancy outcomes (Table 5). A family 
history of VTE (21.6% vs 7.6, p < 0.01), and stroke or MI (11.7 vs 0%, p < 0.01) was more 
common in white women with adverse pregnancy outcomes than in black women. A family 
history of thrombophilia was also more common in white women, but did not reach 
statistical significance (5.8% vs 0%, p = 0.06), There were no racial differences in family 
history of adverse pregnancy outcomes (Table 6).
Discussion
It has been hypothesized that a prothrombotic state may lead to disturbances in utero-
placental circulation resulting in infarction and placental insufficiency which leads to fetal 
loss and other pregnancy complications [19,20]. This has led to frequent thrombophilia 
evaluations and anticoagulant management to prevent fetal loss and other pregnancy 
complications. Despite a higher risk of morbidity and mortality in black women and a higher 
risk of fetal loss, thrombotic risk factors are poorly described in black women. The current 
study demonstrates racial differences in demographic and clinical characteristics of women 
with adverse pregnancy outcomes evaluated in US thrombosis centers. Among women with 
adverse pregnancy outcomes, black women were more likely to have medical comorbidities 
including hypertension and sickle cell disease, more likely to have protein S and 
antithrombin deficiencies, but overall less likely to have an underlying thrombophilia than 
white women. In addition, black women were less likely to report a family history of VTE 
or thrombophilia than white women. In this group of black women with adverse pregnancy 
outcomes, we observed an approximately 27 fold increase in the prevalence of sickle cell 
disease based on prevalence estimates of 1 in 600 in the general US black population [21], 
suggesting the potential importance of this risk factor.
Protein S and antithrombin deficiencies have been associated with pregnancy loss 
[4,6,9,10,22,23]. Our data showed Protein S deficiency to be significantly more common 
among black women with adverse pregnancy outcomes. This difference in protein S 
deficiency between black and white women could not be explained by pregnancy status, or 
by differences in acquired conditions known to be associated with protein S deficiency such 
as sickle cell disease, renal disease, or HIV status; other as yet, unknown acquired etiologies 
of protein S deficiency among black women cannot be excluded. Our study also found more 
frequent antithrombin deficiency among black women. Further studies are required to 
confirm our observed increased prevalence of protein S and antithrombin deficiencies in 
black women with adverse pregnancy outcomes.
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We observed a higher prevalence of family history of thrombophilia, VTE, and stroke or MI 
in white women with adverse pregnancy outcomes suggesting a possible increased role for 
heredity among white women. However, a personal history of VTE, MI and stroke did not 
differ significantly by race in the present study.
White women participating in this study were older than black women, reflecting the 
demographics of pregnancy in the two groups [1]. Since advanced maternal age has been 
shown to be a risk factor for early miscarriage [24], differences in mean maternal age in the 
two groups may confound other racial differences. In addition, obesity is a risk for fetal loss, 
and in this study, blacks were found to have higher BMI, possibly confounding other racial 
differences. History of smoking is another thrombotic risk factor associated with adverse 
pregnancy outcomes, however there were no significant differences in smoking history 
between the racial groups. Our study design did not allow us to adjust for confounding 
factors. Further studies, with an appropriate comparison group are required to evaluate the 
racial differences in thrombotic risk factors after controlling for potential confounding 
factors such as maternal risk factors, and pregnancy complications.
There are limited data on the role of ethnicity and race on the relationship of thrombophilia 
and other thrombotic risk factors with adverse pregnancy outcomes. Black women with 
pregnancy complications were included in two US studies, with one limited to Factor V 
Leiden mutation [25] and one to prothrombin gene mutation [26]. One metaanalysis 
evaluated the confounding influence of ethnicity on the relationship of factor V Leiden and 
adverse pregnancy outcomes [12] and included one study in black South African women 
with pre-eclampsia [27]. Given the paucity of data on the role of race in the relationship of 
adverse pregnancy outcomes with other thrombophilias, our findings warrant additional 
confirmatory studies.
Our study has several limitations including a potential referral bias of women with adverse 
pregnancy outcomes to thrombosis referral centers and limited sample size. The 
characteristics of the two racial groups referred to thrombosis centers may not accurately 
reflect the characteristics of their respective populations in general or high risk obstetrics 
and gynecology settings. However given the multiple participating centers across the US, 
the study population probably does reflect the referred population seen by thrombosis 
specialists and other hematologists in the US. The groups differed with respect to age. Some 
of the differences in thrombotic risk factors such as a history of surgery may have been 
partly a reflection of the age of the subjects. In addition, given that approximately 90% of 
cases of adverse pregnancy outcomes were pregnancy losses, conclusions about other 
adverse pregnancy outcomes such as placenta abruption, IUGR, and preeclampsia may be 
less certain. One additional limitation is that the presence of sickle cell trait was not 
systematically collected, which may be relevant given the high prevalence of sickle cell 
disease observed in this population of black women with adverse pregnancy outcomes.
Whether testing for thrombophilia should be performed in the evaluation of adverse 
pregnancy outcomes, which tests for inherited or acquired thrombophilia should be 
performed, and under what circumstances these tests should be ordered has evolved [28,29]. 
Nevertheless thrombophilia testing and subsequent pregnancy management with 
Philipp et al. Page 6













anticoagulants has been common clinical practice in this population. This multi-center study 
suggests the potential importance of race in examining the role of thrombotic risk factors in 
adverse pregnancy outcomes. The results have potential implications in the identification of 
risk factors and the development of interventions for the prevention of adverse pregnancy 
outcomes in racially diverse and non-white populations.
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Table 1
Characteristics of Study Population with Adverse Pregnancy Outcomes by Race (N = 409).
Characteristics White (N = 343) Black (N = 66) p-value
Age* (in years) mean ± SD 39.1 ± 11.8 33.8 ± 10.4 <0.01
BMI* (kg/m2) mean ± SD 29.1 ± 11.1 31.9 ± 9.6 0.07
Smoking* N (%) 53 (15.5) 9 (13.6) 0.71
BMI** non-pregnant N (%) (N = 246) (N = 29)
<25 90 (36.6) 4 (13.8) 0.01
≥25 156 (63.4) 25 (86.2)
*
At enrollment into registry.
**
N is different because of missing values.
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Table 2
Adverse Pregnancy Outcomes of Study Population by Race (N = 409).
Adverse Pregnancy Outcomes White (N = 343) Black (N = 66) p-value
N (%) N (%)
First Trimester Loss 221 (64.4) 39 (59.1) 0.41
Second Trimester Loss 75 (21.9) 22 (33.3) 0.05
Third Trimester Loss 36 (10.5) 10 (15.2) 0.27
Any Pregnancy Loss 313 (91.3) 63 (95.5) 0.25
Recurrent Pregnancy Loss 159 (46.4) 28 (42.4) 0.56
Intrauterine Growth Restriction 11(3.2) 2 (3.0) 1.00
Preterm delivery 27 (7.9) 3 (4.6) 0.45
Preeclampsia 20 (5.8) 0 0.06
Placental Abruption 17 (5.0) 4 (6.1) 0.76
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Table 3
Thrombophilia in Study Population with Adverse Pregnancy Outcomes by Race (N = 409).
Thrombophilia White (N = 343) Black (N = 66) p-value
N (%) N (%)
Factor V Leiden 65 (19.0) 2 (3.0) <0.01
Prothrombin gene mutation 14 (4.1) 0 0.14
Protein C deficiency 4(1.2) 2(3.0) 0.25
Protein S deficiency 20 (5.8) 10 (15.2) 0.02
Antithrombin deficiency 5(1.5) 4 (6.0) 0.04
Antiphospholipid Syndrome 60 (17.5) 7 (10.6) 0.17
Any Thrombophilia 151 (44.0) 20 (30.3) 0.04
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Table 4
History of Thrombosis in Study Population with Adverse Pregnancy Outcomes by Race (N = 409).
History of Thrombosis White (N = 343) Black (N = 66) p-value
N (%) N (%)
Recurrent VTE 69(20.1) 7(10.6) 0.07
Idiopathic VTE* 80(23.3) 12(18.2) 0.36
Pregnancy related VTE 35(10.2) 12(18.2) 0.06
Post-surgery VTE 37(10.8) 1(1.5) 0.02
Trauma related VTE 12(3.6) 0 0.23
Hormonal associated VTE** 25(7.3) 2(3.0) 0.28
Any VTE 146(42.6) 25(37.6) 0.48
Stroke 28(8.2) 3(4.6) 0.45
Myocardial Infarction 10 (2.9) 0 0.38
*
Not associated with surgery, trauma, cancer, infection, or hormone therapy.
**
Oral contraceptive or HRT use.
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Table 5
Comorbidities by Race in Study Population with Adverse Pregnancy Outcomes (N = 409).
Comorbidities White (N = 343) Black (N = 66) p-value
N (%) N (%)
Diabetes 15 (4.4) 3 (4.6) 1.00
Hypertension 39 (11.4) 17 (25.8) <0.01
Cancer 19 (5.5) 0 0.05
Autoimmune Disease 69 (20.1) 15 (22.7) 0.63
Sickle Cell Disease 0 3 (4.6) <0.01
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Table 6
Family History by Race in Study Population with Adverse Pregnancy Outcomes (N = 409).
Family History White (N = 343) Black (N = 66) p-value
N (%) N (%)
Adverse Pregnancy Outcome 5 (1.5) 1 (1.5) 1.00
Thrombophilia 20 (5.8) 0 0.06
Venous Thromboembolism 74(21.6) 5 (7.6) <0.01
Stroke/MI 40 (11.7) 0 <0.01
Any Family History 107(31.2) 6 (9.1) <0.01
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